SNAP-25 (Synaptosomal-Associated Protein 25)
Introduction
SNAP-25 (Synaptosomal-Associated Protein 25) is a 206-amino acid peripheral membrane protein that functions as the primary t-SNARE (target SNAP receptor) in the synaptic vesicle fusion machinery. Together with [syntaxin-1](/proteins/stx1a-protein) and [VAMP2](/proteins/vamp2-protein), SNAP-25 forms the core SNARE complex that drives Ca²⁺-triggered neurotransmitter release. SNAP-25 is anchored to the presynaptic plasma membrane via palmitoylation of four cysteine residues (Cys 85, 88, 90, 92) and lacks a transmembrane domain, making it unique among SNARE proteins. SNAP-25 dysfunction is implicated in Alzheimer's disease, Parkinson's disease, ALS, and schizophrenia[@sutton1998].
...SNAP-25 (Synaptosomal-Associated Protein 25)
Introduction
SNAP-25 (Synaptosomal-Associated Protein 25) is a 206-amino acid peripheral membrane protein that functions as the primary t-SNARE (target SNAP receptor) in the synaptic vesicle fusion machinery. Together with [syntaxin-1](/proteins/stx1a-protein) and [VAMP2](/proteins/vamp2-protein), SNAP-25 forms the core SNARE complex that drives Ca²⁺-triggered neurotransmitter release. SNAP-25 is anchored to the presynaptic plasma membrane via palmitoylation of four cysteine residues (Cys 85, 88, 90, 92) and lacks a transmembrane domain, making it unique among SNARE proteins. SNAP-25 dysfunction is implicated in Alzheimer's disease, Parkinson's disease, ALS, and schizophrenia[@sutton1998].
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">SNAP-25 Protein Overview</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Synaptosomal-Associated Protein 25</td></tr>
<tr><td><strong>Gene</strong></td><td>[SNAP25](/genes/snap25)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P60880" target="_blank">P60880</a></td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>20p12.1</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>1KTH, 1X5F, 3IP4</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~25.6 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Presynaptic plasma membrane (palmitoylated)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SNARE family (Q-SNARE, SNAP-25/23/29 subfamily)</td></tr>
<tr><td><strong>Tissue Distribution</strong></td><td>Brain (hippocampus, cortex, cerebellum), neuroendocrine cells</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-73e29e3a" style="color:#ce93d8" title="Score: 0.34">Synaptic Vesicle Tau Capture Inhibition...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">242 edges</a></td>
</tr>
</table>
</div>
Structure
SNAP-25 has a distinctive architecture optimized for its role as a membrane-anchored t-SNARE[@sutton1998]:
Primary Structural Regions
- N-terminal region (residues 1-84): Extended coiled-coil forming the first SNARE motif
- Central cysteine-rich domain (residues 85-92): Four palmitoylated cysteines anchoring the protein to membrane
- C-terminal region (residues 93-206): Second SNARE motif forming the coiled-coil bundle
SNARE Motifs
SNAP-25 contributes two α-helical SNARE motifs (SN1 and SN2) to the four-helix SNARE bundle:
| Motif | Residues | Role |
|-------|----------|------|
| SN1 (N-terminal) | 19-83 | Forms the first helix of the SNARE bundle; contains the Q-loop |
| SN2 (C-terminal) | 141-202 | Forms the second helix; completes the t-SNARE core |
This is distinct from VAMP2 (which contributes one helix) and syntaxin-1 (one helix), making SNAP-25 unique as the only SNARE protein contributing two helices.
Membrane Anchoring
SNAP-25 is the only SNARE protein without a transmembrane domain:
- Four cysteine residues (Cys 85, 88, 90, 92) are palmitoylated
- Palmitoylation creates a hydrophobic patch that associates with the inner leaflet of the plasma membrane
- The anchoring is reversible — depalmitoylation releases SNAP-25 from the membrane, regulating SNARE complex availability
| Isoform | Expression | Distribution |
|---------|-----------|--------------|
| SNAP-25a | Ubiquitous | Throughout the nervous system |
| SNAP-25b | Brain-enriched | Highest in hippocampus and cortex |
Post-Translational Modifications
- Palmitoylation: Reversible, regulates membrane association and SNARE complex assembly[@pantano2017]
- Phosphorylation: PKC phosphorylates Ser187, reducing release probability and regulating short-term plasticity[@rosenmund2003]
- Oxidation: [Reactive oxygen species](/entities/reactive-oxygen-species) can modify cysteine residues, disrupting palmitoylation and membrane association
Normal Function
Synaptic Vesicle Exocytosis
SNAP-25 is essential for Ca²⁺-triggered neurotransmitter release[@sdhof2013]:
Vesicle Priming
- SNAP-25 recruits synaptic vesicles to release sites at the active zone
- It interacts with Munc18 and Munc13 to form the primed SNARE complex
- Primed vesicles are held in a fusion-ready state by the partial SNARE complex
SNARE Complex Assembly
SNAP-25 and syntaxin-1 form the t-SNARE complex (heterodimer) at the plasma membrane
VAMP2 on the synaptic vesicle engages with the t-SNARE complex
The ternary SNARE complex (SNAP-25 + syntaxin-1 + VAMP2) zippers from N- to C-terminus
This mechanical force drives fusion pore opening
NSF and α-SNAP disassemble the post-fusion complex for recyclingNeurotransmitter Release
- SNAP-25 is required for quantal content release
- Loss of SNAP-25 severely impairs synchronous release
- Asynchronous release is partially preserved
Synaptic Plasticity
SNAP-25 is a hub for synaptic plasticity modulation[@rosenmund2003]:
- PKC Phosphorylation: Ser187 phosphorylation by PKC reduces SNARE complex stability
- Short-Term Plasticity: PKC-dependent SNAP-25 modulation affects paired-pulse ratio
- Long-Term Potentiation: Activity-dependent SNAP-25 phosphorylation contributes to LTP
- Homeostatic Scaling: Chronic activity changes alter SNAP-25 expression and palmitoylation
Regional and Cellular Distribution
- Brain Regions: Highest expression in [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), cerebellar cortex
- Cell Types: Excitatory glutamatergic and inhibitory GABAergic [neurons](/entities/neurons)
- Subcellular: Concentrated at the presynaptic active zone and synaptic vesicle membranes
Role in Neurodegenerative Diseases
Alzheimer's Disease
SNAP-25 dysfunction contributes to synaptic failure in AD[@zhang2015]:
Synaptic Loss
- Post-mortem AD brains show reduced SNAP-25 protein levels in the hippocampus and cortex[@rao2012]
- SNAP-25 loss correlates with cognitive decline (MMSE scores) and Braak staging
- CSF SNAP-25 fragments serve as a biomarker of synaptic degeneration[@kelley2016]
Aβ Oligomer Effects
- [Aβ oligomers](/proteins/amyloid-beta) impair SNAP-25/syntaxin-1/VAMP2 interactions in lipid mixing assays
- Aβ disrupts SNAP-25 palmitoylation and membrane association
- This reduces the pool of fusion-competent t-SNARE complexes
SNARE Complex Disruption
- Aβ treatment reduces the stability of the ternary SNARE complex
- Impaired SNARE assembly reduces release probability
- Synaptic vesicles fail to fuse efficiently, reducing neurotransmitter release
CSF Biomarker Applications
- SNAP-25 cleavage fragments in CSF indicate synaptic degeneration
- CSF SNAP-25 complements Aβ42 and [tau](/proteins/tau) biomarkers for AD diagnosis
- Longitudinal SNAP-25 changes track cognitive decline progression
Parkinson's Disease
SNAP-25 dysfunction contributes to dopaminergic terminal vulnerability in PD[@ginovart2012]:
Striatal Terminal Deficits
- Reduced SNAP-25 protein in striatal terminals of PD models
- Loss of dopaminergic terminals reduces vesicular dopamine content
- Impaired SNAP-25 function reduces the efficiency of dopamine release
Alpha-Synuclein Interaction
- [α-Synuclein](/proteins/alpha-synuclein) may interfere with SNAP-25 SNARE complex assembly
- α-Syn overexpression reduces SNAP-25 mobility at the active zone
- This contributes to the dopamine release deficit in PD
Therapeutic Potential
- Enhancing SNAP-25 function could improve synaptic transmission in early PD
- Stabilizing the SNAP-25/SNARE complex is a therapeutic strategy
Amyotrophic Lateral Sclerosis (ALS)
Motor Nerve Terminals
- Impaired SNAP-25-dependent exocytosis at motor nerve terminals
- Defects in presynaptic function at the neuromuscular junction (NMJ)
- Altered SNAP-25 expression in ALS spinal cord motor neurons
Neurodegeneration Links
- TDP-43 pathology affects SNAP-25 expression in motor neurons
- Synaptic dysfunction may be an early event in ALS progression
- SNAP-25 as a potential biomarker for motor neuron disease
Schizophrenia
SNAP25 gene polymorphisms are linked to schizophrenia risk[@barr2000]:
- Specific SNAP25 haplotypes increase susceptibility
- SNAP25 variants affect working memory and cognitive function
- Altered SNAP-25 in prefrontal cortex may contribute to psychotic symptoms
Diagnostic and Biomarker Applications
Cerebrospinal Fluid Biomarker
SNAP-25 fragments in CSF indicate synaptic degeneration[@kelley2016]:
- AD Diagnosis: CSF SNAP-25 complements Aβ42 and tau biomarkers
- Disease Progression: Longitudinal changes track cognitive decline
- Sensitivity: SNAP-25 changes appear early in disease course
Brain Imaging
- PET Tracers: SNAP-25-targeted PET agents are under development
- Synaptic Density: SNAP-25 expression correlates with synaptic density measures
Therapeutic Monitoring
- SNAP-25 levels may serve as a pharmacodynamic marker for drugs targeting synaptic function
- Changes in CSF SNAP-25 reflect treatment effects on synaptic integrity
Therapeutic Targeting
| Approach | Mechanism | Status | Indication |
|----------|-----------|--------|------------|
| Botulinum Toxin A | Cleaves SNAP-25 | FDA-approved | Dystonia, spasticity, migraines |
| Botulinum Toxin C | Cleaves SNAP-25 | Research | Experimental therapeutic |
| SNAP-25 Enhancers | Increase expression and function | Preclinical | AD, PD |
| PKC Modulators | Regulate Ser187 phosphorylation | Preclinical | Modulate release probability |
| SNARE Complex Stabilizers | Enhance SNAP-25-Syntaxin-1-VAMP2 interaction | Research | Neuroprotection |
Gene Therapy Approaches
- AAV-SNAP25: Enhancing SNAP-25 expression to restore synaptic function in neurodegeneration
- Palmitoylation Modulators: Enhancing SNAP-25 membrane association
- Splice-Modulating: Targeting disease-specific SNAP25 splice variants
Botulinum Neurotoxin Mechanism
Botulinum neurotoxins (BoNT/A, BoNT/C) cleave SNAP-25 at distinct sites:
- BoNT/A cleaves SNAP-25 at the C-terminal region (residue 197)
- BoNT/C cleaves at the N-terminal region (residue 253 in the longer isoform)
- Cleavage prevents SNAP-25 from forming the SNARE complex
- This blocks acetylcholine release, producing muscle paralysis
- Therapeutic use: Dystonia, spasticity, chronic pain, chronic migraine
Cross-Links
- [SNAP25 Gene](/genes/snap25)
- [VAMP2 Protein](/proteins/vamp2-protein)
- [Syntaxin-1A Protein](/proteins/stx1a-protein)
- [Synaptotagmin-1 Protein](/proteins/syt1-protein)
- [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
- [Amyloid-Beta Protein](/proteins/amyloid-beta)
- [SNARE Complex](/mechanisms/snare-complex)
- [Synaptic Vesicle Cycle](/mechanisms/synaptic-vesicle-cycle)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
External Links
- [UniProt: SNAP-25 (P60880)](https://www.uniprot.org/uniprot/P60880)
- [PDB: SNAP-25 (1KTH)](https://www.rcsb.org/structure/1KTH)
- [NCBI Gene: SNAP25](https://www.ncbi.nlm.nih.gov/gene/6616)